Topadur’s Phase 2a trial of TOP-N53 for systemic sclerosis-associated digital ulcers advances to next dose levels

by | Nov 5, 2026 | News Feeds

Topadur Pharma AG, a Swiss clinical-stage biopharmaceutical company, today announced that the Safety Review Committee of its Phase 2a trial has recommended progression to the next planned dose levels.

Read Original Copy